RxDoctor Payments Data

Fen Wang, MD

Radiation Oncology · Kansas City, KSNPI 1598830176

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by AstraZeneca at 51.6% of the total. Reporting peaked in 2021 at $3,918 and has fallen 95.9% since, to $159 in 2025. Among radiation oncology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,368in general payments, 2019–2025

Across 19 payments — averaging $387.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • GT Medical Technologies, Inc$3K
  • Novocure Inc.$118
  • Medtec LLC$82
  • Varian Medical Systems, Inc.$61
$35,357in research payments, 2019–2025

Across 22 payments — averaging $1607.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GT Medical Technologies, Inc$35K

What the payments were for

  • Consulting fees$3,80052%
  • Travel & lodging$2,09028%
  • Food & beverage$1,39619%
  • Gifts$821%

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$3,800
GT Medical Technologies, Inc15$3,307
Novocure Inc.1$118
Medtec LLC1$82
Varian Medical Systems, Inc.1$61

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,368 in reported general payments places this provider in the 90th percentile of 54 radiation oncology providers in Kansas.

See all radiation oncology providers in Kansas

Medicare billing

Part B allowed, 2024
$134,185
Medicare patients
344
Services billed
1,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pentoxifylline22$1,200
Dexamethasone12$322

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →